CNS Pharmaceuticals Inc (CNSP) - Total Assets
Based on the latest financial reports, CNS Pharmaceuticals Inc (CNSP) holds total assets worth $4.65 Million USD as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore CNSP debt coverage from operations to assess how comfortably operating cash covers total debt obligations.
CNS Pharmaceuticals Inc - Total Assets Trend (2017–2025)
This chart illustrates how CNS Pharmaceuticals Inc's total assets have evolved over time, based on quarterly financial data. See CNS Pharmaceuticals Inc (CNSP) shareholders funds for net asset value and shareholders' equity analysis.
CNS Pharmaceuticals Inc - Asset Composition Analysis
Current Asset Composition (December 2025)
CNS Pharmaceuticals Inc's total assets of $4.65 Million consist of 94.0% current assets and 6.0% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 83.5% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2017–2025)
This chart illustrates how CNS Pharmaceuticals Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see how much is CNS Pharmaceuticals Inc worth.
Key Asset Composition Facts
- Current vs. Non-Current Assets: CNS Pharmaceuticals Inc's current assets represent 94.0% of total assets in 2025, a decrease from 100.0% in 2017.
- Cash Position: Cash and equivalents constituted 83.5% of total assets in 2025, up from 68.2% in 2017.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2017.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
CNS Pharmaceuticals Inc Competitors by Total Assets
Key competitors of CNS Pharmaceuticals Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Samsung Biologics Co Ltd
KO:207940
|
Korea | ₩18.34 Trillion |
|
Revolution Medicines Inc
NASDAQ:RVMD
|
USA | $2.25 Billion |
|
Abivax SA
PA:ABVX
|
France | €584.34 Million |
|
Asymchem Laboratories Tian Jin Co Ltd
SHE:002821
|
China | CN¥20.70 Billion |
|
Ligand Pharmaceuticals Incorporated
NASDAQ:LGND
|
USA | $1.53 Billion |
|
SOLENO THERAPEUT. DL-001
F:6XC
|
Germany | €563.83 Million |
|
SL Science Holding Limited Ordinary Shares
NASDAQ:SLBT
|
USA | $2.82 Million |
|
REMEGEN CO. LTD YC 1
F:REG
|
Germany | €7.25 Billion |
CNS Pharmaceuticals Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.88 | 4.94 | 7.58 |
| Quick Ratio | 0.88 | 4.94 | 7.58 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $-531.40K | $10.94 Million | $12.05 Million |
CNS Pharmaceuticals Inc - Advanced Valuation Insights
This section examines the relationship between CNS Pharmaceuticals Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 109.96 |
| Latest Market Cap to Assets Ratio | 0.88 |
| Asset Growth Rate (YoY) | -0.9% |
| Total Assets | $8.62 Million |
| Market Capitalization | $7.55 Million USD |
Valuation Analysis
Near Book Valuation: The market values CNS Pharmaceuticals Inc's assets close to their book value (0.88x), suggesting investors view the company's assets at approximately fair value.
Slight Asset Contraction: CNS Pharmaceuticals Inc's assets decreased by 0.9% over the past year, which may reflect streamlining or optimization of resources.
Annual Total Assets for CNS Pharmaceuticals Inc (2017–2025)
The table below shows the annual total assets of CNS Pharmaceuticals Inc from 2017 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $8.62 Million | -0.89% |
| 2024-12-31 | $8.70 Million | +411.56% |
| 2023-12-31 | $1.70 Million | -86.97% |
| 2022-12-31 | $13.05 Million | +49.05% |
| 2021-12-31 | $8.76 Million | -44.76% |
| 2020-12-31 | $15.85 Million | +100.37% |
| 2019-12-31 | $7.91 Million | +1057.87% |
| 2018-12-31 | $683.33K | +321.31% |
| 2017-12-31 | $162.19K | -- |
About CNS Pharmaceuticals Inc
CNS Pharmaceuticals, Inc., a clinical pharmaceutical company, engages in the development of therapies for neurology and oncology diseases in the United States. It develops TPI 287, an investigational chemotherapy agent, which is in Phase II clinical trial for the treatment of glioblastoma, metastatic breast cancer with brain metastases, non-small cell lung cancer, castration-resistant prostate ca… Read more